<DOC>
	<DOCNO>NCT02875093</DOCNO>
	<brief_summary>Assessment safety tolerability drug combination determine time treatment , Overall survival ( OS ) response rate patient disease burden , type disease</brief_summary>
	<brief_title>Ph 1 Study ADI-PEG 20 Plus Low Dose Cytarabine Older Patients With AML</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>1 . AML diagnose morphologic ( &gt; 20 % blast blood bone marrow ) histochemical and/or cell surface marker criterion . 2 . Patients AML must fall one following : 1 . Patients AML ( i.e. , &gt; 20 % bone marrow blast ) deem unfit* intensive chemotherapy refractory relapse disease . The patient must refractory least one cycle cytarabine contain regimen least two cycle azacitidine similar hypomethylating agent . 2 . Patients untreated AML ( i.e. , &gt; 20 % bone marrow blast ) intermediate risk karyotype ( MRC risk group ) deem unfit intensive chemotherapy . 3 . Patients untreated AML adverse risk karyotype ( MRC risk group ) deem unfit intensive chemotherapy intolerant azacitidine ( hypomethylating agent ) unable access azacitidine hypomethylating agent . Patients unfit conventional intensive chemotherapy define least one follow base conceptual criterion Ferrara ( 2013 ) : 1 . Advanced age ( 75 year ) . 2 . Cardiac impairment ejection fraction ≤ 50 % heart failure ( NYHA class 2 ) ischemic heart disease stable angina . 3 . Pulmonary impairment : chronic obstructive pulmonary disease ( COPD ) stage 12 ( forced expiratory volume one second [ FEV1 ] &gt; 49 % ) comparable respiratory disease force vital capacity ( FVC ) &gt; 50 % . 4 . Hepatic comorbidity ChildPugh grade A cirrhosis 5 . Chronic kidney disease stage 3 creatinine clearance &gt; 30 mls/min 6 . Any comorbidity physician judge incompatible intensive chemotherapy . 3 . Age &gt; 17 year . 4 . ECOG performance status 02 . 5 . Bone marrow aspirate and/or biopsy test ASS1deficiency . This must fresh sample obtain prior chemotherapy enrollment study . ASS1deficiency require study entry , fresh bone marrow sample must process either within 1 week first study dose ( see Section 10 detail ) . A subject eligible study participation he/she meet exclusion criterion : 1 . Patients uncontrolled infection require intravenous ( IV ) antibiotic/antiviral therapy eligible entry onto study ; patient prophylactic antibiotic antiviral acceptable . 2 . Pregnancy lactation . 3 . Expected noncompliance . 4 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure ( New York Heart Association Class III IV ) , unstable angina , ventricular cardiac arrhythmia ( ventricular ectopy ) , severe pulmonary comorbidity : COPD grade 34 ( FEV1 &lt; 50 % ) comparable document pulmonary disease FVC &lt; 50 % , dyspnea rest require oxygen home , cognitive impairment : current mental illness require psychiatric hospitalization , institutionalization intensive outpatient management , uncontrolled current cognitive status ( confirmed specialist ; dependence caregiver permit long well control ) , severe hepatic comorbidity : liver ChildPugh grade BC cirrhosis acute viral hepatitis , social situation would limit compliance study requirement DIC cause coagulopathy correctable factor replacement . 5 . Subjects antileukemia treatment prior enter study recover baseline ( except alopecia ) or≤ Grade 1 AEs , deem irreversible effect prior cancer therapy . AEs &gt; Grade 1 consider safety risk Sponsor Investigator may allow upon agreement .</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>